Despite advances in surgical procedures, radiation, and chemotherapy the outcome for patients with glioblastoma (GBM) remains poor. While GBM cells express antigens that are potentially recognized by T cells, GBMs prevent the induction of GBM-specific immune responses by creating an immunosuppressive microenvironment. The advent of gene transfer has allowed the rapid generation of antigen-specific T cells as well as T cells with enhanced effector function. Here we review recent advances in the field of cell therapy with genetically modified T cells and how these advances might improve outcomes for patients with GBM in the future. © 2013 Krebs, Rodríguez-Cruz, DeRenzo and Gottschalk.
CITATION STYLE
Krebs, S., Rodríguez-Cruz, T. G., DeRenzo, C., & Gottschalk, S. (2013). Genetically modified T cells to target glioblastoma. Frontiers in Oncology. https://doi.org/10.3389/fonc.2013.00322
Mendeley helps you to discover research relevant for your work.